English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduTest With Smartphone App May Predict Blood Clot Risk
People who take the blood-thinning medication warfarin to prevent blood clots—which can lead to heart attacks—need frequent blood testing to ensure that the drug is working. Currently, this testing occurs in a clinical laboratory or with expensive at-home testing systems. It involves a particular measure of the time it takes for a clot to form, called prothrombin time (PT), and calculating the international normalized ratio (INR) so doctors can compare results between different tests or laboratories.
A team led by Kelly Michaelsen, MD, PhD, of the University of Washington developed a test that quickly and inexpensively determines PT/INR using a smartphone. The test uses a smartphone’s built-in vibration motor and camera to track movement of a copper particle in a drop of blood. To see whether the test works, the researchers tested blood from 140 anonymous patients at the University of Washington Medical Center. The team also tested blood from 79 patients with known blood-clotting issues. In both groups, the new test produced results similar to laboratory PT/INR tests.
As a next step, Michaelsen is planning to research whether patients can use the new test by themselves at home. She envisions it being helpful for people in rural areas, to minimize long and increasingly expensive trips to doctors.
Michaelsen hopes her test will lead to more people spending more time in the desirable PT/INR range, which would mean they are not at risk for clots or (on the flipside) for uncontrolled bleeding. “The goal is to decrease complications while making PT/INR testing more convenient and less expensive,” she said.
Improving Kidney Stone Analysis and Treatment
Kidney stones are common, affecting more than 1 in 10 people. If left untreated, these hard deposits made of minerals and salts can lead to severe pain, urinary tract infections, and loss of kidney function. Effective treatment and prevention rely on knowing what stones are made of, which is often determined through a manual process using Fourier transform infrared spectroscopy (FTIR). However, mistakes in FTIR interpretation and reporting can lead to inappropriate treatments and undermine efforts to prevent future kidney stones through medication, diet, and lifestyle changes.
To improve diagnosis and better guide treatment, researchers led by Patrick Day, MPH, MLS (ASCP)cm, of Mayo Clinic created a group of artificial intelligence (AI)-trained algorithms that analyze FTIR kidney stone composition results. The researchers then conducted a study to determine whether the algorithms could find errors in kidney stone composition results that had been reviewed and reported by a clinical laboratory technologist.
Within the 12-month study period, these AI-trained algorithms reviewed manual analyses of 81,517 kidney stones. While the technologist’s and AI’s interpretations agreed 90% of the time, the researchers determined that manual entry errors and/or incorrect technologist interpretations before use of AI occurred at a rate nearly 8 times higher than after the start of AI use.
“Clinical laboratories continuously adopt technology to improve the accuracy of lab tests. By adopting AI, clinical laboratories can reduce errors in results sent to physicians. This study is an example of how the fields of laboratory medicine, data science, information technology, and biostatistics can work together to improve patient care,” said Day.
Abstract Information
AACC Annual Scientific Meeting registration is free for members of the media. Reporters can register online here: https://www.xpressreg.net/register/aacc0722/media/landing.asp
Abstract B-183: Micro-mechanical PT/INR testing using smartphones will be presented during:
Scientific Poster Session
Wednesday, July 27
9:30 a.m. – 5 p.m. (presenting author in attendance from 1:30 – 2:30 p.m.)
Abstract A-140: Classification of kidney stone composition using an artificial intelligence model: Twelve month prospective study demonstrates improvements in quality and patient safety will be presented during:
Scientific Poster Session
Tuesday, July 26
9:30 a.m. – 5 p.m. (presenting author in attendance from 1:30 – 2:30 p.m.)
Both sessions will take place in the Poster Hall of the Clinical Lab Expo show floor at the McCormick Place Convention Center in Chicago.
About the 2022 AACC Annual Scientific Meeting & Clinical Lab Expo
The AACC Annual Scientific Meeting offers 5 days packed with opportunities to learn about exciting science from July 24-28. Plenary sessions will explore artificial intelligence-based clinical prediction models, advances in multiplex technologies, human brain organogenesis, building trust between the public and healthcare experts, and direct mass spectrometry techniques.
At the AACC Clinical Lab Expo, more than 750 exhibitors will fill the show floor of the McCormick Place Convention Center in Chicago with displays of the latest diagnostic technology, including but not limited to COVID-19 testing, artificial intelligence, mobile health, molecular diagnostics, mass spectrometry, point-of-care, and automation.
About AACC
Dedicated to achieving better health through laboratory medicine, AACC brings together more than 70,000 clinical laboratory professionals, physicians, research scientists, and business leaders from around the world focused on clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of progressing laboratory science. Since 1948, AACC has worked to advance the common interests of the field, providing programs that advance scientific collaboration, knowledge, expertise, and innovation. For more information, visit www.aacc.org.
